Mary F. Hebert

Mary F. Hebert

Auto-generated profile, based on publicly available information

Mary F. Hebert

Department of Pharmacy University of Washington, School of Pharmacy Seattle Washington USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
EHEunjin Hong
Eunjin Hong
MHMary F. Hebert
Mary F. Hebert
EFEmily Fay
Emily Fay
GTGrant Turner
Grant Turner
PEPatricia Eshaghian
Patricia Eshaghian
PBPaul M. Beringer
Paul M. Beringer
The use of elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with increased fertility in women with cystic fibrosis (CF) and is increasingly used during pregnancy to support both maternal and fetal health. However, little is known about the pharmacokinetics (PK) of ETI during pregnancy, which is crucial for optimizing its efficacy and safety. This study aimed to predict the PK of ETI during pregnancy and to determine the maternal dose required to achieve therapeutic concentrations in both the maternal and fetus. The pregnancy physiological‐based pharmacokinetic (PBPK) model within the Simcyp Simulator was used to predict the maternal and feto‐placental exposure of ETI. Placental kinetics were parameterized using permeability parameters determined from the physicochemical properties of these compounds. The model closely predicted the observed data, with the observed ETI maternal plasma concentrations, cord concentrations, and infant plasma concentrations mostly falling within the range of predicted 5th to 95th percentiles. Steady‐state simulations up to gestational week 40 predicted a continuous decline in ETI concentrations, with the AUC declining to 32.4–37.5% of baseline levels by week 40. However, the 5th percentile of trough concentrations for ETI consistently remained above the efficacy thresholds, both in mother and fetus. Therefore, it appears reasonable to maintain standard dosing regimen during pregnancy, complemented by careful monitoring. A clinical trial, such as the ongoing Maternal and Fetal Outcomes in the Era of Modulators (MAYFLOWERS) study, is required to further confirm the efficacy and safety of ETI in this population.

2 January 2024 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Open access
YHYeon Mi Hwang
Yeon Mi Hwang
RRRyan T. Roper
Ryan T. Roper
SPSamantha N. Piekos
Samantha N. Piekos
DEDaniel A. Enquobahrie
Daniel A. Enquobahrie
MHMary F. Hebert
Mary F. Hebert
JHJennifer Hadlock
Jennifer Hadlock
There is uncertainty around the safety of SSRIs for treating depression during pregnancy. Nevertheless, the use of SSRIs has been gradually increasing, especially during the COVID-19 pandemic period. We aimed to (1) characterize maternal depression rate and use of SSRIs in a recent 10-year period, (2) address confounding by indication, as well as socioeconomic and environmental factors, and (3) evaluate associations of the timing of SSRI exposure in pregnancy with risk for preterm birth (PTB), low birthweight (LBW), and small for gestational age (SGA) infants among women with depression before pregnancy. We conducted propensity score-adjusted regression to calculate odds ratios (ORs) of PTB, LBW, and SGA. We accounted for maternal/pregnancy characteristics, comorbidity, depression severity, time of delivery, social vulnerability, and rural residence. There were 50.3% and 40.3% increases in the prevalence rate of prenatal depression and prenatal SSRI prescription rate during the pandemic. We identified women with depression ≤180 days before pregnancy (n = 8406). Women with no SSRI order during pregnancy (n = 3760) constituted the unexposed group. The late SSRI exposure group consisted of women with an SSRI order after the first trimester (n = 3759). The early-only SSRI exposure group consisted of women with SSRI orders only in the first trimester (n = 887). The late SSRI exposure group had an increased risk of PTB of OR = 1.5 ([1.2,1.8]) and LBW of OR = 1.5 ([1.2,2.0]), relative to the unexposed group. Associations between late SSRI exposure and risk of PTB/LBW were similar among a subsample of patients who delivered during the pandemic. These findings suggest an association between PTB/LBW and SSRI exposure is dependent on exposure timing during pregnancy. Small for gestational age is not associated with SSRI exposure.

5 March 2023 in medRxiv
Verified
Preprint
Open access
PDF file
YHYeon Mi Hwang
Yeon Mi Hwang
RRRyan T. Roper
Ryan T. Roper
SPSamantha N. Piekos
Samantha N. Piekos
DEDaniel A. Enquobahrie
Daniel A. Enquobahrie
MHMary F. Hebert
Mary F. Hebert
JHJennifer Hadlock
Jennifer Hadlock
Purpose There is uncertainty around the safety of SSRIs for treating depression during pregnancy. We aimed 1) to address confounding by indication, as well as socioeconomic and environmental factors associated with depression and 2) evaluate associations of timing of SSRI exposure in pregnancy with the risk of preterm birth and related outcomes (small for gestational age and low birthweight) among women with depression before pregnancy. Methods We conducted propensity score-adjusted regression to calculate odds ratios (OR) of preterm birth, small for gestational age, and low birth weight. We accounted for maternal/pregnancy characteristics, pre-pregnancy comorbidity/depression severity, social vulnerability, rural health disparity, and pre-natal depression severity. We additionally conducted a drug-specific analysis and assessed the impact of other classes of antidepressants within our cohort of interest. Results Among women with a history of depression, we identified women with indication of depression ≤ 180 days before pregnancy (n=6,408). Women with no SSRI order during pregnancy (n=3,122) constituted the unexposed group (no SSRI exposure group). The late SSRI exposure group consisted of women with an SSRI order after the first trimester (n=2,596). The early-only SSRI exposure group consisted of women with SSRI orders only in the first trimester (n=691). Late SSRI exposure group had an increased risk of preterm birth of OR=1.7 ([1.3,2.2], p<0.0001), and low birth weight of OR = 1.7 ([1.3,2.4], p<0.001), relative to the no SSRI exposure group. Conclusions These findings suggest associations between preterm birth/low birthweight and SSRI exposure is dependent on exposure timing during pregnancy. Small for gestational age is not associated with SSRI exposure.

12 October 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
AAAurora K Authement
Aurora K Authement
MHMary F Hebert
Mary F Hebert
EFEmily E Fay
Emily E Fay
NINina Isoherranen
Nina Isoherranen
Pregnancy results in multiple physiological changes that impact drug disposition. For example, hepatic CYP3A activity and renal transporter‐mediated clearance increase in late pregnancy, but the time course of these changes across pregnancy is not known. Endogenous biomarkers offer a minimally invasive approach to characterize pharmacokinetic changes during pregnancy and postpartum. The goal of this study was to determine whether 6β‐OH‐cortisol formation clearance (CL f,OHCOL ) can be used as a biomarker of hepatic CYP3A activity during pregnancy. Thus, we measured cortisol, cortisone, and 6β‐OH‐cortisol in plasma and urine from 47 women during late pregnancy and postpartum and calculated the CL f,OHCOL , unbound fraction (f u ), unbound intrinsic CL f (CL f,u,int,OHCOL ), and renal clearance (CL r ). CL f,OHCOL increased 1.3‐fold in late pregnancy while cortisol f u decreased significantly. CL f,u,int,OHCOL increased 1.8‐fold, corresponding to a 2.1‐fold increase in hepatic CYP3A activity. The increase in CL f,u,int,OHCOL was observed in CYP3A5 expressors and in CYP3A5 nonexpressors. In late pregnancy, the increase in CL r,cortisol and CL r,OHCOL exceeded the calculated increase in filtration clearance, suggesting increased transporter‐mediated secretion. The decreased f u of cortisol during pregnancy was captured by a model incorporating increased expression of corticosteroid binding globulin (CBG) and increased binding affinity of cortisol to CBG. These data suggest that CL f,u,int,OHCOL is a robust biomarker of CYP3A activity during pregnancy and could be used in future studies to characterize the time course of changes in CYP3A activity across gestation and postpartum. Further, CL r,cortisol and CL r,OHCOL may be biomarkers of kidney OCT and MATE activity and could be used to evaluate kidney transporter activity during pregnancy.